Notice of Intent to Award a Sole Source Contract � Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak
FDA · FOOD AND DRUG ADMINISTRATION
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation OC-2026-135667 in this department, oldest first.
- Jul 24, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
Procurement Type: Sole Source Simplified Acquisition Procedures (SAP) Purchase Order for Commercial Items Authority: FAR Part 6.103-1, Only One Responsible Source Subject: Notice of Intent to Award a Sole Source Contract � Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak Description: The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to The University of Liverpool for the Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak, in accordance with the authority under FAR Part 6.103-1, Only One Responsible Source. This pro… (show all)
curement is being conducted under simplified acquisition procedures in accordance with FAR Part 12 (RFO). The NAICS Code for this action is 541714 - Research and Development in Biotechnology (except Nanobiotechnology). The primary objective of this requirement is to obtain critical reagents such as procure reference standards and internal standards to perform bioanalytical method development and sample analysis to determine the quantification of CYP enzyme substrates/metabolites and transporter substrates in hepatocyte experiments. Responses: Responses to this notice should be sent to Ryan Alexander at ryan.alexander@fda.hhs.gov by 5:00 pm July 29, 2026. This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.
Who won similar work
4 award notices on SAM.gov in the last 24 months. Matched by: Same agency (FDA), same NAICS 541714.
Single-winner award sizes (4): middle half $16.5M to $67.7M, median $33.4M; range $15.7M to $120.8M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| Please_See_Spreadsheet Silver Spring MD 20993 USA | 3 | $153.2M | Oct 8, 2026 |
| TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC | 1 | $50.0M | Sep 16, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Oct 8, 2026Please_See_Spreadsheet Silver Spring MD 20993 USA$120.8MFY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceNo listed company matched (Materiality N/A)
- Jan 13, 2026Please_see_Spreadsheet Silver Spring MD 20993 USA$16.7MFY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceNo listed company matched (Materiality N/A)
- Jan 8, 2026Please_see_Spreadsheet Silver Spring MD 20993 USA$15.7MFY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceNo listed company matched (Materiality N/A)
- Sep 16, 2025TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC$50.0MFood and Drug Administration (FDA) Office of Clinical Pharmacology (OCP) � Multi-phase/Multi- site Clinical Studies and Laboratory Support Indefinite Delivery-Indefinite Quantity (IDIQ) Type ContractNo listed company matched (Materiality N/A)
Competitive landscape
For the 2 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Food & Drug Administration (FDA) since 2024 (0 filings)
- 0 of their lobbyists list a past Food & Drug Administration (FDA) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 129 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.